Study of Fenofibrate Treatment for High-Grade Cervical Dysplasia and Invasive Cervical Cancer in Adult Women

What this Trial Is About

Researchers are studying how Fenofibrate, a cholesterol-lowering drug, can be used to treat HPV-positive cervical cancers and cervical dysplasia. Early research suggests Fenofibrate may restore normal p53 function, which helps prevent tumor growth, and alter tumor metabolism to stop tumor development. This study aims to explore Fenofibrates effects on genes and proteins in cervical intraepithelial neoplasia and invasive cervical carcinoma. Participants with high-grade dysplasia will take 200 mg of Fenofibrate daily starting at enrollment for 2 to 4 weeks until their excisional procedure. Those with invasive cervical cancer will also receive 200 mg daily for 2 to 4 weeks until their definitive hysterectomy or chemoradiation treatment. Fenofibrate administration continues during this pre-treatment window to evaluate its impact on the tumors. During the study, researchers will assess changes in p53 levels and tumor metabolic status up to six weeks after enrollment. They will collect tissue samples to investigate genetic and protein changes. Fenofibrate tolerability will also be monitored. Participants will be closely followed through their surgical or chemoradiation procedures, with the study concluding upon completion of these assessments.

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma